ClinicalTrials.gg
CompletedNCT07710560Updated Sep 17, 2026

A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection

A Phase 1 interventional study of KL0011034 injection and Alfentanil Hydrochloride Injection in Chronic Pain, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.

Enrollment
32nd of 34
27 · median 80
Started
2026
with 3 others
Phase 1
8 of 43
none open now
Registered
42nd of 43
by date

Among the 43 studies in Chronic Pain with a site in China, this one is the 32nd largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 in phase 1, and was the 42nd registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Chronic Pain with a site in China, or all of them as a file.
02

Study summary

To evaluate the pharmacokinetic interaction of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the safety and tolerability of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the effect of alfentanil hydrochloride injection on the pharmacodynamics of KL0011034 injection.

Read the detailed description

This study will be conducted among the participants with moderate-to-severe non-cancerous chronic pain, aiming to evaluate the drug-drug interactions between KL0011034 injection and alfentanil hydrochloride injection. The study consists of two parts:

Part 1 trial:

A single-center, randomized, open, parallel design is adopted to evaluate the safety, tolerability and pharmacodynamic characteristics of the combined use of KL0011034 injection and alfentanil hydrochloride injection.

It is planned to enroll 9 patients with moderate-to-severe non-cancerous chronic pain. All participants will be randomly assigned to one of the three dose groups in a 1:1:1 ratio, with 3 participants in each group. They will complete a single combined administration and undergo pharmacodynamic and safety evaluations.

Based on the results of Part 1 trial, KL0011034 injection will select the maximum dose with acceptable safety among the three doses for the second part of the study.

Part 2 trial:

A single-center, randomized, open, three-sequence, three-period crossover trial design is adopted to evaluate the PK interactions, safety and tolerability of the combined use of KL0011034 injection and alfentanil hydrochloride injection, as well as the effect of alfentanil hydrochloride injection on the pharmacodynamics of KL0011034 injection.

It is planned to enroll 18 patients with moderate-to-severe non-cancerous chronic pain. All participants will be randomly assigned to one of the three sequences A, B, and C in a 1:1:1 ratio, with 6 participants in each sequence. They will complete three periods of open administration and undergo PK blood sampling, pharmacodynamic and safety evaluations, with a 3-day washout period for each period.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • chronic pain
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients with moderate-to-severe non-cancerous chronic pain (Age: 18\~55 years, NRS score≥4);
  2. Body Weight: Male≥50.0kg, Female≥45.0kg; 19.0 ≤≤ 26.0;
  3. There were no abnormalities in physical examination, vital signs, 12-lead , chest x-ray, abdominal B-ultrasound, laboratory tests;

Exclusion criteria

Exclusion Criteria:

  1. Allergy or Drug ;
  2. Medical History;
  3. History of anesthesia accident, history of serious adverse reactions of anesthesia, or family history of anesthesia accidents, or to general anesthesia;
  4. Dyspnoea or suspected difficult airway, or predicting difficult endotracheal intubation;
  5. History of bronchial asthma, , sleep apnea syndrome;
  6. History of adrenal insufficiency or adrenal tumor or hereditary heme biosynthesis disorder or hereditary acute porphyria;
  7. History of any surgery within 3 months;
  8. History of any Medication within 14 days;
  9. History of any inducers or inhibitors of or CYP2C19 enzymes within 30 days;
  10. History of any clinical study within 3 months;
  11. History of any vaccine within 1 month;
  12. History of any drug abuse;
  13. Needle sickness, Hematosickness;
  14. Massive blood loss (> 400 mL) in the past 3 months;
  15. Female volunteers are pregnant or lactating;
  16. History of unprotected sex within 2 weeks;
  17. Heavy smoker ( more than 5 cigarettes/day) within 3 months;
  18. History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months;
  19. Heavy caffeine intake;
  20. History of grapefruit, xanthine-rich foods intake within 48 hours;
  21. Positive alcohol test;
  22. Positive nicotine test;
  23. Positive drugs of abuse test result.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Sequence A

    Period 1, 6 participants will receive KL0011034 injection; Period 2, 6 participants will receive Alfentanil Hydrochloride Injection; Period 3, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    Sequence B

    Period 1, 6 participants will receive Alfentanil Hydrochloride Injection; Period 2, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 3, 6 participants will receive KL0011034 injection;

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

  • Experimental
    Sequence C

    Period 1, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 2, 6 participants will receive KL0011034 injection; Period 3, 6 participants will receive Alfentanil Hydrochloride Injection;

    Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Number of reported Adverse Events

    Safety and tolerability was assessed by the number of volunteers with adverse events.

    Time frame: 24 hours post-dose for each period

Secondary outcomes

  1. PK parameter Cmax in plasma

    Maximum peak plasma concentration (Cmax) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. Cmax of Alfentanil combining with or without KL0011034 injection.

    Time frame: 24 hours post-dose for each period

  2. PK parameter Tmax in plasma

    Time of Cmax (Tmax) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. Tmax of Alfentanil combining with or without KL0011034 injection.

    Time frame: 24 hours post-dose for each period

  3. PK parameter AUC0-t in plasma

    Area under the concentration-time curve (AUC0-t) from time zero to time "t" of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. AUC0-t of Alfentanil combining with or without KL0011034 injection.

    Time frame: 24 hours post-dose for each period

  4. PK parameter AUC0-∞ in plasma

    AUC from time zero to infinity (AUC0-∞) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. AUC0-∞ of Alfentanil combining with or without KL0011034 injection.

    Time frame: 24 hours post-dose for each period

  5. PK parameter t1/2 in plasma

    Terminal-phase elimination half-life (t1/2) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. t1/2 of Alfentanil combining with or without KL0011034 injection.

    Time frame: 24 hours post-dose for each period

  6. Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale

    MOAA/S is a commonly used clinical sedation assessment scale, ranging from 0 to 5, which helps clinicians determine the level of sedation in patients. A score of 5 indicates full consciousness, whereas a score of 0 indicates deep coma. Lower scores correspond to deeper levels of sedation.

    Time frame: Day 1 for each period

  7. Electroencephalogram bispectrality index (BIS) monitoring

    BIS is the most widely used method for the continuous monitoring of sedation depth in clinical anesthesia. BIS values range from 0 to 100, where 100 represents complete wakefulness and 0 indicates complete cortical electrical inhibition.

    Time frame: Day 1 for each period

  8. Loss of eyelash reflex

    The eyelash reflex is a commonly used clinical method to assess the level of consciousness in patients. Gentle stimulation of the eyelashes with a cotton swab normally elicits a blink; absence of this response indicates loss of the eyelash reflex.

    Time frame: Day 1 for each period

  9. Modified Aldrete Scoring (Aldrete) Scale

    The Modified Aldrete Score is the most widely used standardized tool for assessing discharge readiness from post-anesthesia care unit (PACU). It evaluates five parameters: activity, respiration, blood pressure consciousness, and SpO₂. Ranging from 0 to 10, the higher the score, the better the quality of recovery.

    Time frame: Day 1 for each period

07

Study locations

1 site
  • The Third XIANGYA Hospital of Central South University
    Changsha, Hunan 410205, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Aug 2026, 0 months.

Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 0 months is below that.

Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2026
First posted
Jul 17, 2026
StartActual
Jul 15, 2026
Primary completionActual
Aug 12, 2026
CompletionActual
Aug 12, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710560
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jul 15, 2026
Primary completion
Aug 12, 2026
Completion
Aug 12, 2026
Last update
Sep 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KL0011034 · Alfentanil

Start the discussion